Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines

The role of bortezomib in the treatment of acute lymphoblastic leukemia

(2016) Mohammad Faizan Zahid   Future Oncology

Bortezomib, Dexamethasone, Mitoxantrone, and Vinorelbine (BDMV)

(2016) Kee K. Yeo et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

(2016) Meletios A Dimopoulos et al.   LANCET ONCOLOGY

How I treat high-risk myeloma

(2015) S. Lonial et al.   BLOOD

Ikaros and leukaemia

(2015) Linda Olsson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Asparaginase-associated toxicity in children with acute lymphoblastic leukemia

(2015) Nobuko Hijiya et al.   LEUKEMIA & LYMPHOMA

Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1

(2013) Teresa S. Hawley et al.   AMERICAN JOURNAL OF HEMATOLOGY

Carfilzomib

(2013) K. M. Kortuem et al.   BLOOD

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study

(2013) A J Jakubowiak et al.   LEUKEMIA

Altered expression of miR-24, miR-126 and miR-365 does not affect viability of childhood TCF3-rearranged leukemia cells

(2013) F Akbari Moqadam et al.   LEUKEMIA

IKZF1deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan

(2013) Daisuke Asai et al.   Cancer Medicine

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

(2012) D. S. Siegel et al.   BLOOD

Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

(2012) Y. H. Messinger et al.   BLOOD

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

(2012) Ravi Vij et al.   BRITISH JOURNAL OF HAEMATOLOGY

Development of Peptide-Based Reversing Agents for P-Glycoprotein-Mediated Resistance to Carfilzomib

(2012) Lin Ao et al.   MOLECULAR PHARMACEUTICS

Resistance to the Translation Initiation Inhibitor Silvestrol is Mediated by ABCB1/P-Glycoprotein Overexpression in Acute Lymphoblastic Leukemia Cells

(2011) Sneha V. Gupta et al.   AAPS Journal

Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19)

(2010) K. Hirose et al.   BLOOD

Establishment of a new Philadelphia chromosome−positive acute lymphoblastic leukemia cell line (SK-9) with T315I mutation

(2010) Seiichi Okabe et al.   EXPERIMENTAL HEMATOLOGY

Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress

(2010) M Ri et al.   LEUKEMIA

Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): A report from the therapeutic advances in childhood leukemia (TACL) consortium

(2010) Yoav Messinger et al.   PEDIATRIC BLOOD & CANCER

KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation

(2009) Y. Shiotsu et al.   BLOOD

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

(2009) F. Parlati et al.   BLOOD

Proteasome Inhibition Causes Regression of Leukemia and Abrogates BCR-ABL-Induced Evasion of Apoptosis in Part through Regulation of Forkhead Tumor Suppressors

(2009) Z. Jagani et al.   CANCER RESEARCH

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies

(2009) O. A. O'Connor et al.   CLINICAL CANCER RESEARCH

Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma

(2009) D Gutman et al.   LEUKEMIA

Chemo-sensitivity in a panel of B-cell precursor acute lymphoblastic leukemia cell lines, YCUB series, derived from children

(2009) Hiroaki Goto et al.   LEUKEMIA RESEARCH

Deletion ofIKZF1and Prognosis in Acute Lymphoblastic Leukemia

(2009) Charles G. Mullighan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia

(2008) J. J. Yang et al.   BLOOD

Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor

(2008) Chikara Hirase et al.   LEUKEMIA RESEARCH

BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros

(2008) Charles G. Mullighan et al.   NATURE

Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program

(2007) Peter J. Houghton et al.   PEDIATRIC BLOOD & CANCER